Application of ADRA2A antagonist in preparation of medicine for treating inflammatory bowel disease
The inhibition of tyramine-ADRA2A signaling axis by ADRA2A antagonist solves the problem of ineffective treatment of inflammatory bowel disease, significantly improves the proliferation and intestinal stem cells and provides a new treatment for Crohn's disease method.
Patent Information
- Application Number
- CN202410541748.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-30
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-04-30
AI Technical Summary
The existing treatment methods for inflammatory bowel disease cannot effectively cure the disease, and most patients do not respond to biological therapies, and new targets and treatment methods are urgently needed.
Develop ADRA2A antagonists, which are used to inhibit intestinal stem cell proliferation and restore intestinal growth through an antagonist of the tyramine-ADRA2A signaling axis, are used to prevent and treat inflammatory bowel diseases, especially Crohn's disease.
It significantly improves the proliferation ability of intestinal stem cells, repairs damaged intestines, and relieves inflammation, providing new treatments for inflammatory bowel diseases, especially Crohn's disease.
Smart Images

Figure BDA0004821178500000021 
Figure BDA0004821178500000031 
Figure BDA0004821178500000041
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicine, and in particular to the use of an ADRA2A antagonist in the preparation of a drug for preventing and / or treating inflammatory bowel disease, in particular Crohn's disease. Background Art
[0002] Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease of unknown etiology, with a lifelong recurring clinical tendency, and this chronic intestinal inflammation also increases the risk of colon cancer in patients. Studies have shown that higher prevalence and incidence rates are observed in countries with higher levels of urbanization and industrialization. Currently, there are more than 10 million IBD patients in the world. At the same time, with the continuous advancement of urbanization and industrialization, the living environment, dietary lifestyle and habits of the Chinese people have undergone earth-shaking changes. IBD has now developed into the most common type of disease in my country's digestive system. It is estimated that by 2025, the number of IBD patients in China may reach at least 1.5 million.
[0003] Inflammatory bowel disease (IBD) mainly includes two types of diseases: Crohn's disease (CD) and ulcerative colitis (UC). IBD has unique physiological and pathological clinical characteristics, which greatly reduces the patient's quality of life, increases the burden of treatment, and is also a high-risk factor for inducing intestinal cancer. In addition, the commonly used clinical treatments for IBD currently include: 1. Surgery to resect the damaged part of the gastrointestinal tract; 2. Non-targeted immunosuppressive therapy, such as immunomodulators such as 5-aminosalicylic acid and corticosteroids; 3. Targeted biological therapy, using neutralizing antibodies to neutralize proinflammatory cytokines (such as neutralizing antibodies for TNF-α), neutralize cytokines of specific pathogenic immune subgroups (such as anti-IL-12 and anti-IL-23 antibodies), block signal transduction downstream of related signaling pathways (JAK inhibitors, etc.), or regulate the trafficking of lymphocytes (such as anti-α4β7 integrin antibodies). Biological therapy is effective for many patients, but up to 30-40% of patients do not respond to initial treatment, and 50% of patients lose response. Current treatments cannot cure IBD.
[0004] Therefore, there is an urgent need for new targets for the treatment of IBD so that new treatments can be developed. Summary of the invention
[0005] The object of the present invention is to provide an ADRA2A antagonist, which can have excellent preventive and / or therapeutic effects on inflammatory bowel disease, especially Crohn's disease.
[0006] In a first aspect, the present invention provides use of an antagonist of the tyramine-ADRA2A signaling axis in the preparation of a medicament for preventing and / or treating inflammatory bowel disease and restoring stem cell growth / organoid growth.
[0007] In a preferred embodiment, the stem cells are intestinal stem cells; and the organoids are intestinal organoids.
[0008] In a specific embodiment, the antagonist of the tyramine-ADRA2A signaling axis is a tyramine inhibitor.
[0009] In a preferred embodiment, the tyramine inhibitor is a substance that destroys tyramine, or a substance that kills or inhibits tyramine-producing microorganisms.
[0010] In a preferred embodiment, the tyramine-producing microorganisms include but are not limited to: Enterococci.
[0011] In a preferred embodiment, the tyramine inhibitor is an antibiotic against enterococci, such as penicillins and vancomycin.
[0012] In a preferred embodiment, the tyramine inhibitor is an enterococcal phage virotherapy.
[0013] In a specific embodiment, the tyramine inhibitor is a substance that inhibits the production of tyramine by related microorganisms, for example: 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9).
[0014] In a specific embodiment, the antagonist of the tyramine-ADRA2A signaling axis is an ADRA2A antagonist.
[0015] In a specific embodiment, the ADRA2A antagonist includes, but is not limited to, small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, and siRNA of the gene encoding ADRA2A.
[0016] In a specific embodiment, the small molecule antagonist of ADRA2A includes, but is not limited to, yohimbine, idazoxan and 2-methoxyimidazolidine; preferably yohimbine.
[0017] In a preferred embodiment, the CAS numbers and structural formulas of the yohimbine, imidazoxan and 2-methoxyimidazolidine are as follows:
[0018]
[0019] In a specific embodiment, the inflammatory bowel disease includes, but is not limited to, Crohn's disease and ulcerative colitis; preferably Crohn's disease.
[0020] In a second aspect, the present invention provides a pharmaceutical composition comprising an antagonist of the tyramine-ADRA2A signaling axis and other therapeutic drugs for inflammatory bowel disease and a pharmaceutically acceptable excipient.
[0021] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is a tyramine antagonist.
[0022] In a preferred embodiment, the tyramine inhibitor is a substance that destroys tyramine, or a substance that kills or inhibits tyramine-producing microorganisms.
[0023] In a preferred embodiment, the tyramine-producing microorganisms include but are not limited to: Enterococci.
[0024] In a preferred embodiment, the tyramine inhibitor is an antibiotic against enterococci, such as penicillins and vancomycin.
[0025] In a preferred embodiment, the tyramine inhibitor is a bacteriophage virotherapy against enterococci.
[0026] In a preferred embodiment, the tyramine inhibitor is a substance that inhibits the production of tyramine by related microorganisms, for example: 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9).
[0027] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is an ADRA2A antagonist.
[0028] In a preferred embodiment, the ADRA2A antagonist includes, but is not limited to, small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, and siRNA of the gene encoding ADRA2A.
[0029] In a preferred embodiment, the small molecule antagonist of ADRA2A includes, but is not limited to, yohimbine, idazoxan and 2-methoxyimidazolidine; preferably yohimbine.
[0030] In a preferred embodiment, the CAS numbers and structural formulas of the yohimbine, imidazoxan and 2-methoxyimidazolidine are as follows:
[0031]
[0032] In a third aspect, the present invention provides an antagonist of the tyramine-ADRA2A signaling axis or a pharmaceutical composition comprising the antagonist of the tyramine-ADRA2A signaling axis for use in preventing and / or treating inflammatory bowel disease.
[0033] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is a tyramine inhibitor.
[0034] In a preferred embodiment, the tyramine inhibitor is a substance that destroys tyramine, or a substance that kills or inhibits tyramine-producing microorganisms.
[0035] In a preferred embodiment, the tyramine-producing microorganisms include but are not limited to: Enterococci.
[0036] In a preferred embodiment, the tyramine inhibitor is an antibiotic against enterococci, such as penicillins and vancomycin.
[0037] In a preferred embodiment, the tyramine inhibitor is an enterococcal phage virotherapy.
[0038] In a preferred embodiment, the tyramine inhibitor is a substance that inhibits the production of tyramine by related microorganisms, for example: 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9).
[0039] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is an ADRA2A antagonist.
[0040] In a preferred embodiment, the ADRA2A antagonist includes, but is not limited to, small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, and siRNA of the gene encoding ADRA2A.
[0041] In a preferred embodiment, the small molecule antagonist of ADRA2A includes, but is not limited to, yohimbine, idazoxan and 2-methoxyimidazolidine; preferably yohimbine.
[0042] In a preferred embodiment, the CAS numbers and structural formulas of the yohimbine, imidazoxan and 2-methoxyimidazolidine are as follows:
[0043]
[0044] In a preferred embodiment, the inflammatory bowel disease includes, but is not limited to, Crohn's disease and ulcerative colitis; preferably Crohn's disease.
[0045] In a preferred embodiment, the pharmaceutical composition comprises an antagonist of the tyramine-ADRA2A signaling axis and other therapeutic drugs for inflammatory bowel disease and a pharmaceutically acceptable excipient.
[0046] In a fourth aspect, the present invention provides use of tyramine in inhibiting intestinal stem cells or preparing an intestinal stem cell inhibitor.
[0047] In a preferred embodiment, the intestinal stem cell inhibitor is a drug for preventing or treating intestinal cancer.
[0048] In a fifth aspect, the present invention provides a method for preventing and / or treating inflammatory bowel disease, comprising administering a preventively and / or therapeutically effective amount of an antagonist of the tyramine-ADRA2A signaling axis or a pharmaceutical composition comprising an antagonist of the tyramine-ADRA2A signaling axis to a subject in need of prevention and / or treatment of inflammatory bowel disease.
[0049] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is a tyramine inhibitor.
[0050] In a preferred embodiment, the tyramine inhibitor is a substance that destroys tyramine, or a substance that kills or inhibits tyramine-producing microorganisms.
[0051] In a preferred embodiment, the tyramine-producing microorganisms include but are not limited to: Enterococci.
[0052] In a preferred embodiment, the tyramine inhibitor is an antibiotic against enterococci, such as penicillins and vancomycin.
[0053] In a preferred embodiment, the tyramine inhibitor is a bacteriophage virotherapy against enterococci.
[0054] In a preferred embodiment, the tyramine inhibitor is a substance that inhibits the production of tyramine by related microorganisms, for example: 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9).
[0055] In a preferred embodiment, the antagonist of the tyramine-ADRA2A signaling axis is an ADRA2A antagonist.
[0056] In a preferred embodiment, the ADRA2A antagonist includes, but is not limited to, small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, and siRNA of the gene encoding ADRA2A.
[0057] In a preferred embodiment, the small molecule antagonist of ADRA2A includes, but is not limited to, yohimbine, idazoxan and 2-methoxyimidazolidine; preferably yohimbine.
[0058] In a preferred embodiment, the CAS numbers and structural formulas of the yohimbine, imidazoxan and 2-methoxyimidazolidine are as follows:
[0059]
[0060] In a preferred embodiment, the inflammatory bowel disease includes, but is not limited to, Crohn's disease and ulcerative colitis; preferably Crohn's disease.
[0061] In a preferred embodiment, the pharmaceutical composition comprises an antagonist of the tyramine-ADRA2A signaling axis and other therapeutic drugs for inflammatory bowel disease and a pharmaceutically acceptable excipient.
[0062] In a preferred embodiment, the subject is a mammal; preferably, the subject is a human.
[0063] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 It shows that tyramine (bacterial metabolite)-ADRA2A signaling axis exists on intestinal stem cells and is positively correlated with intestinal inflammation. Figure 1 A shows Lgr5-GFP hi Intestinal stem cells and Lgr5-GFP lo Expression patterns of nine adrenergic receptors in progenitor cells (GSE67324), Figure 1 B shows the bubble diagram of the expression profiles of nine adrenergic receptors in single cells of mouse intestinal epithelium. Figure 1 C shows ADRA2A immunostaining in the intestinal epithelium of Lgr5-GFP reporter mice. Figure 1 D shows the schematic diagram of PRESTO-Tango GPCR assay for ADRA2A. Figure 1 E shows the screening of 87 microbial metabolites using the ADRA2A PRESTO-Tango GPCR detection system to find potential agonists of ADRA2A. The fold difference represents the ratio of metabolite-activated luminescence to control luminescence, and the results show that tyramine specifically activates ADRA2A signaling. Figure 1 F shows the structural formulas of tyramine and norepinephrine. Figure 1 G shows the dose response dynamics of tyramine and norepinephrine in the ADRA2A PRESTO-Tango assay, n=9. Figure 1 H shows a schematic diagram of the BRET2 assay for detecting ADRA2A activation. The ratio of the luminescence values of GFP2 and RLuc8 was calculated as the BRET2 ratio. Figure 1 I shows the dose response dynamics of tyramine and norepinephrine in the ADRA2ABRET2 assay. N=6. Figure 1 J shows LC-MS quantification of fecal tyramine (ug / g wet weight feces) in healthy controls (n=36) and CD patients (n=51) in an IBD cohort (USTC). Each point represents an independent individual. Figure 1K shows the ADRA2A mRNA expression levels in healthy (n = 50) and Crohn's disease CD (n = 124) biopsy samples, and the analysis data are from the public dataset of the Human Microbiome Project 2 (HMP2). All data are expressed as Mean ± SEM, and the unpaired Student t test was used for statistical analysis of the two groups of data, ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; The data represent the results of two to three independent experiments;
[0065] Figure 2 It was shown that tyramine activated ADRA2A receptor to inhibit intestinal stem cell proliferation. Figure 2 A shows the schematic diagram of tyramine activation of ADRA2A and ADRA2A receptor knockout blocking strategy. Adra2a KO: Adra2a gene deficiency mice, Figure 2 B shows representative images of organoid culture under different tyramine concentrations, scale bar: 500 μm; Figure 2 C shows quantification of organoid formation efficiency on day 4. “Organoid formation efficiency” was calculated as the ratio of the number of viable organoids to the number of crypts initially seeded per well, n = 3. Figure 2 Representative images of crypt-cultured intestinal organoids from Lgr5-GFP reporter mice are shown in D, scale bar: 100 μm. Figure 2 E shows the flow cytometry analysis of intestinal organoids with DAPI - Epcam + CD24 low Lgr5-GFP in epithelial cells + The proportion of intestinal stem cells; Figure 2 Lgr5-GFP is shown in F + Quantification of intestinal stem cell percentage. N = 3 per group. All data are expressed as mean ± sem, ****P < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; data are representatives of two or three independent experiments. Figure 2 GO analysis of significantly down-regulated genes in tyramine-treated samples is shown below G, N = 3 independent samples. Figure 2 H shows the expression heat map of genes related to intestinal stem cell (ISC) proliferation and cell cycle regulation in the transcriptome of the tyramine-treated and control groups; Figure 2 I shows qRT-PCR analysis of cell cycle genes in organoids from WT and Adra2a KO mice under the action of 100 μM tyramine. All data are expressed as mean ± sem, ****P < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; data are representatives of two or three independent experiments;
[0066] Figure 3 Bioinformatics analysis showed that tyramine-producing enterococci were enriched in patients with enteritis, among which, Figure 3 A shows the phylogenetic distribution of tyrDC in the human microbiome. The homology of the Enterococcus faecalis V583 TyrDC protein in the Human Microbiome Project reference genome was queried using BLASTP, and the results were displayed on a phylogenetic tree based on 16S rRNA alignment, where tyrDC was mainly distributed in the Enterococcus genus. Figure 3 B shows the differential distribution of the gut microbiota in patients from geographically diverse Crohn's (CD) cohorts, including the United States and France. Figure 3 Figure C shows the differential distribution of intestinal microbiota in patients with different disease states, including progression and remission, in CD cohorts from different geographical locations. Figure 3 D shows the results of 16S sequencing analysis of the intestinal microbiome of patients with Crohn's disease. The principal coordinate analysis (PCOA) based on the unweighted and weighted unifrac distances between the fecal microbial communities of healthy donors (n=36) and patients with Crohn's disease (CD) (n=51) showed that the microbiome of patients with Crohn's disease was significantly altered. Figure 3 E shows the differential distribution of intestinal microbiota in patients from the USTC CD cohort, with Enterococci being enriched in patients with Crohn's disease. Figure 3 F shows the evolutionary phylogenetic diagram of the evolutionary relationships of bacterial taxa significantly associated with CD patients found by LefSe analysis;
[0067] Figure 4 The Enterococcus-tyramine-ADRA2A signaling axis aggravates the progression of intestinal inflammation. Figure 4 A shows a schematic diagram of the workflow for inducing enteritis under tyramine administration. ADRA2A ΔIEC Mice and their littermates ADRA2A WT Mice were given tyramine via drinking water (including a water control group), and 4 weeks later, a mouse colitis model was induced using 2.5% DSS. Figure 4 BG shows ADRA2A exposed to water or tyramine WT and ADRA2A ΔIEC Mice were treated with 2.5% DSS to induce colitis phenotype. Figure 4 B shows the changes in mouse body weight, N = 9 in each group; Figure 4 C and Figure 4 D shows the length of mouse colon; Figure 4 E and Figure 4 F shows colon pathology scores. Figure 4 G shows a schematic diagram of the workflow for enterococcal colonization-induced enteritis. WTAfter antibiotic pretreatment, mice were gavaged with WT and tyrDC-deficient (△tyrDC) Enterococcus faecalis strains every 2 days for 2 weeks. Fecal microbiota transplantation (FMT) was then performed, and 2.5% DSS colitis model was established 1 day later. Figure 4 H shows the weight changes of mice in each group, N = 6 mice in each group; Figure 4 I and Figure 4 J shows the changes in colon length of mice in each group; Figure 4 K and Figure 4 L shows the changes in colon length of mice in each group. Scale bar, 50 μm. Data are expressed as mean ± sem ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; Data are representatives of two or three independent experiments;
[0068] Figure 5 ADRA2A antagonists have the potential to treat intestinal inflammation. Figure 5 A shows a schematic diagram of the blocking effects of three ADRA2A antagonists, yohimbine, idazoxan, and 2-methoxyimidazolidine, on the tyramine-ADRA2A signaling axis. Figure 5 B shows a representative picture of organoid culture. Figure 5 C shows the quantitative statistics of organoid culture. Three ADRA2A antagonists, yohimbine, idazoxan, and 2-methoxyimidazole, were treated in vitro in organoid culture. The results showed that all three antagonists could restore the inhibition of tyramine on intestinal stem cells. Figure 5 D shows a schematic diagram of intestinal inflammation induced by single bacterial colonization of clinically isolated Enterococcus in mice, and ADRA2A knockout group and yohimbine treatment group were designed respectively. WT and ADRA2A △IEC After antibiotic pretreatment, mice were gavaged with clinically isolated Enterococcus faecium strains once every 2 days for 2 weeks. Fecal flora transplantation (FMT) was then performed, and 2.5% DSS colitis model was established 1 day later. In the Yohimbine treatment group, Yohimbine (2 mg / kg) was injected intraperitoneally starting from 1 week after Enterococcus colonization, and injected once every 1 day for a total of 8 injections. Figure 5 E shows the weight changes of mice in each group, N = 6 mice in each group; Figure 5 F and Figure 5 G shows the changes in colon length of mice in each group; Figure 5 H and Figure 5 I shows the changes in colon length of mice in each group. Scale bar, 50 μm. Data are expressed as mean ± sem ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; Data are representatives of two or three independent experiments. DETAILED DESCRIPTION
[0069] After extensive and in-depth research, the inventors unexpectedly discovered a completely new way to regulate intestinal stem cells. Specifically, the inventors found that tyramine produced by enterococci (a widely reported enteritis pathogen) activates the α-2a adrenergic receptor (ADRA2A), inhibits the proliferation of ISCs and aggravates the pathological damage of DSS-induced colitis. Furthermore, the inventors designed targeted drugs for the discovered pathogen-host target signal axis, and developed a treatment plan that uses ADRA2A receptor-specific antagonists to target and intervene in pathogen-host interaction receptors to alleviate colitis. At the same time, it also proves the important role of intestinal stem cells in promoting mucosal repair and treating intestinal inflammation. The present invention was completed on this basis.
[0070] the term
[0071] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0072] Tyramine
[0073] Tyramine is a natural compound commonly found in plants and animals. Its chemical formula is C8H 11 NO, and has the structure shown below:
[0074]
[0075] Inflammatory bowel disease
[0076] Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease of unknown etiology. A large number of studies have shown that intestinal inflammation is mainly the result of damage to the intestinal epithelial barrier, which leads to an imbalance in the interaction between the immune system and the symbiotic microorganisms in the intestinal cavity. In a specific embodiment, the inflammatory bowel disease of the present invention includes but is not limited to Crohn's disease and ulcerative colitis; preferably Crohn's disease.
[0077] The intestinal epithelium is a rapidly renewing single layer of cells tightly linked together. The intestinal epithelium is composed of different types of single layers of cells that form a series of luminal protrusions (villi) and cup-shaped invaginations (crypts). The small intestinal cells include six different cell lines, which can be divided into two major categories: cells that absorb the contents of the lumen and secretory cells. Our intestinal epithelial cells have the ability to renew rapidly, and can be fully renewed approximately every 3 to 5 days. Old epithelial cells will fall off from the top of the villi into the lumen, and the production of new intestinal epithelial cells is achieved by the continuous proliferation and differentiation of intestinal stem cells. Lgr5 +Intestinal stem cells (ISCs) are long-lived multipotent adult stem cells in the intestine, located in the stem cell niche at the bottom of the crypt. They rapidly generate all intestinal epithelial cell types in the small intestine and colon within the lineage "stripe" extending from the crypt to the tip of the villus, and are therefore responsible for most of the sustained steady-state epithelial cell conversion. Competition for limited niche space within the stem cell niche enables precise regulation of the number and fate of intestinal stem cells. At the same time, under conditions of epithelial damage, the ISC niche resists pathogenic stimuli and transforms them into epithelial regeneration through hyperstable adjustments. MAP3K2-regulated intestinal basal cells (MRISCs) are new regulatory components in the intestinal stem cell niche. During intestinal inflammatory damage, they can rely on MAP3K2 to enhance the WNT signaling of intestinal stem cells, thereby promoting epithelial repair and alleviating enteritis. Stable intestinal stem cells (Lgr5 + ISCs play an important role in epithelial repair, especially in the repair of epithelial damage during intestinal inflammation. Therefore, it is necessary to understand the stem cell plasticity of ISCs and the role of Lgr5 in the repair of epithelial damage. + Biological properties of ISCs underlying distinct adaptations to niches during epithelial injury and subsequent repair.
[0078] At the same time, a large number of studies have shown that the functional defects of inflammatory bowel disease (IBD) are also reflected in the imbalance of intestinal microbial ecology. The intestinal microbial ecology of patients with intestinal inflammation is significantly imbalanced, mainly manifested as reduced microbial diversity, enrichment of harmful bacteria and reduction of beneficial bacteria; the intestinal microbiome promotes abnormal immune responses in patients with genetic IBD susceptibility through various mechanisms, and the disordered microbiome in turn aggravates the symptoms of enteritis. However, whether bacteria associated with intestinal inflammation can directly affect intestinal stem cells, inhibit epithelial cell repair, and thus aggravate the progression of enteritis has not been clearly reported.
[0079] Tyramine-ADRA2A signaling axis and ADRA2A receptor
[0080] The term "tyramine-ADRA2A signaling axis" used in this article refers to the complete pathway in which symbiotic microorganisms in the mammalian intestine produce a small molecule metabolite, tyramine, which specifically activates the ADRA2A receptor and affects the proliferation of intestinal stem cells.
[0081] The term "ADRA2A receptor" as used herein is a receptor expressed on intestinal stem cells. The ADRA2A receptor, α2-adrenergic receptor, is a member of the G protein-coupled receptor superfamily and is involved in regulating the release of neurotransmitter molecules from sympathetic and central nervous system adrenergic neurons. The sympathetic nervous system regulates cardiovascular function by activating adrenergic receptors in the heart, blood vessels, and kidneys. Studies on mice have shown that the ADRA2A receptor is required for the release of presynaptic transmitters from the cardiac sympathetic nervous system and central noradrenergic neurons. The ADRA2A receptor is also involved in catecholamine signaling through the extracellular regulated protein kinase 1 and 2 (ERK1 / 2) pathway. Current studies have not yet determined a clear association between the ADRA2A receptor and disease.
[0082] The inventors have discovered that intestinal stem cells have a tyramine-ADRA2A signaling axis. Tyramine-producing enterococci activate ADRA2A receptors through tyramine to downregulate the expression of cell cycle-related genes, thereby inhibiting the proliferation of intestinal stem cells and preventing intestinal stem cells from repairing damaged intestines.
[0083] Inhibitors of the tyramine-ADRA2A signaling axis
[0084] The term "inhibitor" used in this article mainly refers to substances that block and regulate specific signal pathways to achieve control of cell functions and biological processes; the term "antagonist" mainly refers to substances that do not cause biological effects themselves after binding to receptor proteins, but block the effects mediated by the receptor agonist.
[0085] The inventors found that enterococci are enriched in the intestines of Crohn's patients, and tyramine produced by enterococci can activate the ADRA2A receptor on intestinal stem cells (ISC), inhibit intestinal stem cell proliferation, and hinder intestinal epithelial repair, thereby aggravating the development of intestinal inflammation. Therefore, antagonists of the tyramine-ADRA2A signal axis can inhibit tyramine from activating the ADRA2A receptor on intestinal stem cells, thereby increasing the proliferation of intestinal stem cells, thereby repairing damaged intestines and improving intestinal inflammation. On this basis, the present invention provides the use of antagonists of the tyramine-ADRA2A signal axis in the preparation of drugs for preventing and / or treating inflammatory bowel disease. At the same time, antagonists of the tyramine-ADRA2A signal axis can also be used to restore stem cell growth / organoid growth. Therefore, the present invention also provides the use of antagonists of the tyramine-ADRA2A signal axis in the preparation of drugs for preventing and / or treating the restoration of stem cell growth / organoid growth. Preferably, the stem cells are intestinal stem cells.
[0086] Based on the teachings of the present invention, those skilled in the art can know that the inhibitor of the tyramine-ADRA2A signaling axis can be a tyramine inhibitor. For example, the tyramine inhibitor can be a substance that destroys tyramine, or a substance that can kill or inhibit the production of tyramine by microorganisms (including but not limited to enterococci), or a substance that can inhibit the production of tyramine by related microorganisms. For example, in a specific embodiment, the tyramine inhibitor can be penicillins and vancomycin, or enterococcal phage virus biological preparations, so as to eliminate enterococcal colonization in the intestine; or, the tyramine inhibitor can be 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9), so as to inhibit the production of tyramine by related microorganisms.
[0087] Based on the teachings of the present invention, those skilled in the art may also know that the inhibitory effect on the tyramine-ADRA2A signal axis may also be an antagonist of the ADRA2A receptor. Therefore, the inhibitor of the tyramine-ADRA2A signal axis may also be an antagonist of ADRA2A. Those skilled in the art are aware of various specific forms of ADRA2A antagonists, including but not limited to: small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, siRNA of the coding gene of ADRA2A, and the like. In a specific embodiment, ADRA2A specific antagonists include yohimbine, imidazoxan and 2-methoxyimidazolidinone. The CAS numbers and structural formulas of the yohimbine, imidazoxan and 2-methoxyimidazolidinone are as follows:
[0088]
[0089] These ADRA2A antagonists block the activation of ADRA2A on intestinal stem cells during the pathogenesis of intestinal inflammation, thereby enhancing the repair of damaged intestinal epithelium by intestinal stem cells, and thus play an important role in the treatment of Crohn's disease enriched with enterococci or tyramine.
[0090] In addition, the inventors found in in vitro experimental studies that ADRA2A specific antagonists, especially yohimbine, can significantly inhibit tyramine's activation of ADRA2A and restore tyramine's inhibition of intestinal stem cell proliferation. Therefore, ADRA2A specific antagonists, including yohimbine, idazoxan and 2-methoxyimidazole, significantly restore the proliferation function of intestinal stem cells during intestinal inflammation, enhance the damage and repair function of intestinal epithelial cells, and provide a new method for the treatment of inflammatory bowel disease, especially Crohn's disease, that is, to treat Crohn's disease by regulating intestinal stem cells.
[0091] Furthermore, in view of the fact that the inventors have found that tyramine inhibits the proliferation of intestinal stem cells (ISC) by activating the ADRA2A receptor on the intestinal stem cells (ISC), tyramine can be used to inhibit intestinal stem cells or prepare intestinal stem cell inhibitors. Those skilled in the art know that intestinal stem cells are located at the base of the intestinal mucosal crypts, that is, the basal crypts are the cell bank of intestinal stem cells. The abnormal proliferation of intestinal stem cells is considered to be an important risk of intestinal cancer. Therefore, tyramine inhibition of intestinal stem cells can effectively inhibit the abnormal proliferation of intestinal stem cells and reduce the chance of intestinal canceration, thereby becoming a potential new solution for the treatment of intestinal cancer. In other words, in certain pathological conditions, inhibiting intestinal stem cells is also extremely important.
[0092] Therefore, the present invention also provides the use of tyramine in inhibiting intestinal stem cells or preparing an intestinal stem cell inhibitor. The intestinal stem cell inhibitor can be used as a drug for preventing or treating intestinal cancer.
[0093] Pharmaceutical composition
[0094] Based on the antagonist of the tyramine-ADRA2A signaling axis of the present invention, the present invention provides a pharmaceutical composition, which comprises the antagonist of the tyramine-ADRA2A signaling axis of the present invention. However, based on the teachings of the present invention and the routine operation in the art, it is known that other therapeutic drugs for inflammatory bowel disease can also be included in the pharmaceutical composition of the present invention. Therefore, the present invention also covers a pharmaceutical composition comprising an antagonist of the tyramine-ADRA2A signaling axis of the present invention and other therapeutic drugs for inflammatory bowel disease.
[0095] Based on the teachings of the present invention and common knowledge in the art, those skilled in the art know that the pharmaceutical composition of the present invention can be formulated into a preparation form suitable for various administration routes, for example, an oral preparation, such as a capsule.
[0096] The pharmaceutical composition of the present invention may include a preventive or therapeutically effective amount of an antagonist of the tyramine-ADRA2A signaling axis of the present invention or other therapeutic drugs for inflammatory bowel disease. The effective amount is an amount sufficient to improve or alleviate in some way the symptoms associated with enteritis. Such an amount can be administered as a single dose, or can be administered according to an effective treatment regimen. The dosage may cure enteritis, but administration may also generally be for the purpose of improving the symptoms of enteritis, such as significantly alleviating symptoms such as weight loss, shortened colon length, and release of inflammatory factors in subjects with enteritis. The dosage administered can be determined by a clinician based on the patient's age, health and weight, the type of concurrent treatment, the frequency of treatment, and the desired therapeutic benefit.
[0097] The pharmaceutical preparation of the present invention can be administered to any mammal as long as they can obtain the therapeutic effect of the compound of the present invention. The most important of these mammals is human.
[0098] The pharmaceutical composition of the present invention can be manufactured in a known manner. The pharmaceutical composition of the present invention contains pharmaceutically acceptable excipients, such as sugars such as lactose or sucrose, mannitol or sorbitol; cellulose preparations or calcium phosphates, such as tricalcium phosphate or calcium hydrogen phosphate; and binders, such as starch paste, including corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or polyvinyl pyrrolidone. If necessary, disintegrants such as the starches mentioned above, as well as carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or its salts, such as sodium alginate, can be added. Auxiliary agents are particularly flow regulators and lubricants, for example, silica, talc, stearates, such as magnesium calcium stearate, stearic acid or polyethylene glycol. If necessary, the tablet core can be provided with a suitable coating that can resist gastric juice. For this purpose, concentrated sugar solutions can be applied. This solution may contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and / or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. To prepare a coating resistant to gastric juices, suitable cellulose solutions may be used, for example cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate. Dyes or pigments may be added to the coating of the tablet or lozenge core, for example, for identification or to characterize the combination of active ingredient doses.
[0099] Treatment options for inflammatory bowel disease
[0100] Based on the antagonist or pharmaceutical composition of the tyramine-ADRA2A signaling axis of the present invention, the inventors also provide a method for preventing and / or treating inflammatory bowel disease. The method comprises administering a preventive and / or therapeutically effective amount of an antagonist of the tyramine-ADRA2A signaling axis or a pharmaceutical composition comprising an antagonist of the tyramine-ADRA2A signaling axis to a subject who needs to prevent and / or treat inflammatory bowel disease. The subject may be a mammal; preferably a human. The dosage, timing of administration, mode of administration, etc. during the treatment process can be determined by the clinician according to the patient's age, health and weight, the type of concurrent treatment, the frequency of treatment, and the desired therapeutic benefit.
[0101] Advantages of the present invention:
[0102] 1. In the present invention, it is first discovered that intestinal stem cells have a tyramine-ADRA2A signaling axis;
[0103] 2. In the present invention, it is first discovered that tyramine-producing enterococci inhibit the proliferation of intestinal stem cells by activating the ADRA2A receptor through tyramine, thereby preventing the intestinal stem cells from repairing the damaged intestine and aggravating intestinal inflammation;
[0104] 3. In the present invention, an antagonist of the tyramine-ADRA2A signaling axis is used to inhibit the activation of the ADRA2A receptor on intestinal stem cells by tyramine, thereby restoring the proliferation of intestinal stem cells, repairing damaged intestines, and alleviating intestinal inflammation;
[0105] 4. In the present invention, a variety of antagonists of the tyramine-ADRA2A signaling axis are provided and verified, among which yohimbine, idazoxan and 2-methoxyimidazolidine significantly restore the proliferation function of intestinal stem cells during intestinal inflammation and enhance the damage repair function of intestinal epithelial cells;
[0106] 5. The present invention lays a brand new material and theoretical foundation for the treatment of inflammatory bowel disease, especially Crohn's disease.
[0107] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0108] Example
[0109] Materials and Methods
[0110] In the following examples, GraphPad 8.0.2 statistical software was used to process the data. The experimental results were expressed as mean ± standard deviation. The data were tested by ANOVA, and the T test was used for pairwise comparison. The Tukey multiple comparison test was used for multiple groups. P < 0.05 (*) indicated a significant difference, P < 0.01 (**) indicated a very significant difference, and P < 0.001 (***) indicated a very significant difference.
[0111] All experimental animals and mice in the following examples are of C57BL / 6 background, mainly including mice of the following genotypes:
[0112] Table 1. Experimental mouse information
[0113]
[0114] The Lgr5 lineage-tracing mice (Lgr5-EGFP-IRES-CreERT2; Rosa26 LSL -tdTomato ) and Villin1-cre:ADRA2A fl / flTransgenic mice were obtained by crossbreeding the above mice. All animal experiments were finally conducted on mice aged 6 to 10 weeks. All mice were kept in the SPF animal room of the Experimental Animal Center of the School of Life Sciences of the University of Science and Technology of China, and the care of each mouse strictly complied with the regulations of the University of Science and Technology of China on experimental animal breeding management. All mouse experiments were carried out in strict accordance with the management regulations of the Experimental Animal Ethics Committee of the University of Science and Technology of China (ethics number: USTCACUC192401055).
[0115] Example 1. Tyramine-ADRA2A signaling axis exists in intestinal stem cells
[0116] 1. Experimental process:
[0117] Bioinformatics methods were used to analyze the transcriptome of intestinal stem cells and the single-cell transcriptome data of intestinal epithelial cells to obtain the expression pattern of ADRA2A. Immunofluorescence staining was used to clarify the expression pattern of ADRA2A on intestinal stem cells. Antibody information used: rabbit anti-ADRA2A (1:50, Lifespan LS-C804463), goat anti-rabbit secondary antibody (Invitrogen).
[0118] 2. Screening of potential ADRA2A agonists using small molecule metabolites derived from gut bacteria
[0119] The inventors constructed a small molecule metabolite containing 87 intestinal microorganisms, and screened 87 microbial metabolites based on the PRESTO-Tango GPCR method to find potential agonists of the ADRA2A receptor: HTLA cells were transfected with 20 ng of human ADRA2A Tango expression plasmid per well, and the microbial metabolite stock solution was diluted and added to each well at a final concentration of 100 μM. After 18 hours, the culture medium in the culture dish was replaced with 20 μL / well of BrightGlo reagent (Promega). After incubation at room temperature for 10 minutes, the plate was read on Envision (Perkin Elmer). Each microbial metabolite was repeated 4 times, and the drug buffer was used as a negative control. The results show a double change (i.e., the reaction of each metabolite / the reaction of the negative control).
[0120] 3. Bioluminescence resonance energy transfer (BRET) assay
[0121] This study used the bioluminescence resonance energy transfer (BRET) experimental method to monitor the dissociation of heterotrimeric G proteins induced by ADRA2A activation. In the inactivated state of GPCR, due to the aggregation of heterotrimeric G proteins, the fluorescent groups carried by the groups are in close contact, and the luminescent group RLuc8-Gα can effectively excite the fluorescent receptor GFP2-Gβγ, and the system detects the GFP signal; after GPCR activation, the dissociation of the heterotrimeric G protein complex causes the luminescent group RLuc8-Gα to be unable to effectively excite the fluorescent receptor GFP2-Gβγ, and the GFP2 signal is reduced. The experimental process is as follows:
[0122] 1) Four plasmids: pcDNA3.1 expression plasmid vector of human ADRA2A receptor, expression plasmid vector of Gαi1 and Renilla luciferase (RLuc8) fusion protein, Gβ3 and C-terminal fused GFP Gγ9 protein expression plasmid vector, were co-transfected into HEK293T cells (ATCC CRL-11268; mycoplasma free) at a mass ratio of 1:1:1:1.
[0123] 2) The transfected cells were plated in a 96-well transparent cell culture plate and cultured in DMEM medium containing 10% fetal bovine serum (100 μL / well, 30,000 cells). After overnight incubation, the culture medium was replaced with 40 μL / well of 7.5 μM coelenterazine 400a (Promega).
[0124] 3) After 2 minutes of diffusion, 20 μL / well of agonist (3x) was added in drug buffer. Each well was read for 15 seconds on a MithrasLB940 multimode microplate reader using 395nm (RLuc8) and 510nm (GFP2) emission filters. The ratio of GFP2 / RLuc8 per well was calculated using GraphPad Prism 8.0 and plotted as a function of drug concentration.
[0125] 4. Liquid chromatography-mass spectrometry (LC-MS) quantitative detection of tyramine content
[0126] The expression level of ADRA2A in Crohn's disease patients in the Human Microbiome Project (Hmp2) was analyzed. At the same time, a Crohn's disease cohort was established (36 healthy subjects and 51 Crohn's disease patients). Fecal samples of patients in the cohort were taken to detect tyramine content using liquid chromatography-mass spectrometry (LC-MS).
[0127] 1) To isolate tyramine from fecal samples, 80 mg of human or 50 mg of mouse fecal samples were resuspended in 1 mL of cold extraction solvent methanol / acetonitrile / H2O (2:2:1, v / v / v), vortexed thoroughly, and incubated on ice for 20 minutes. Centrifuged at 14000 g for 20 minutes at 4°C. The supernatant was collected and dried in a vacuum centrifuge at 4°C.
[0128] 2) To separate tyramine from bacterial supernatant, the bacterial culture was centrifuged at 2000g for 30 minutes at 4°C. 100 μL of supernatant was resuspended in 400 μL of extraction solvent methanol / acetonitrile (2:2, v / v), vortexed thoroughly, incubated on ice for 20 minutes, and centrifuged at 14000g for 20 minutes at 4°C. The supernatant was collected and dried in a vacuum centrifuge at 4°C.
[0129] 3) The dried sample was redissolved in 100 μL of acetonitrile / water (1:1, v / v) solvent and injected at a dose of 1 μL. Tyramine was quantified using an AB ExionLCTM liquid chromatography system (AB SCIEX) and an AB 5600+TripleTOF system (ABSCIEX). Liquid chromatography separation: XBridge BEH C18 column (100 mm × 2.1 mm; 2.5 μm; Waters Corp., USA) was used with a flow rate of 0.4 mL / min. The mobile phase solvent was a mixture of 0.1% (v / v) formic acid-10 mM ammonium acetate aqueous solution (a) and 0.1% formic acid-80% (v / v) methanol-20% (v / v) acetonitrile (B). The gradient flow was set to 35% (v / v) B for 0.5 min, linearly increased to 60% B in the next 2.5 min, linearly increased to 80% B in the next 7 min, linearly increased to 90% B in the next 6 min, linearly decreased to 35% B in the next 4.5 min, and finally maintained at this composition for 2.5 min. All data were collected in positive ion mode.
[0130] 4) Raw data were processed using Peak View 2.2 software based on m / z values and sample retention times. Metabolites were identified by matching observed m / z signals (+ / -10 ppm) and chromatographic retention times with those observed for commercial metabolite standards (Selleckchem). Tyramine was detected using parallel reaction monitoring, m / z = 138.0913, chromatographic retention time = 1.5 min signal, and confirmed by MS / MS fragmentation patterns.
[0131] 5. Experimental results:
[0132] The present inventors used flow cytometry-sorted Lgr5-GFP from Lgr5-eGFP-IRES-CreERT2 knock-in mice (referred to as Lgr5-GFP reporter mice) to identify Lgr5-GFP. hi ISCs and Lgr5-GFP lo Based on the public mRNA-Seq dataset of progenitor cells, the inventors found that α2a-adrenergic receptor (Adra2a) is a + Adra2a is one of the most abundant GPCRs expressed in intestinal stem cells (ISCs). Adra2a is also a receptor in the adrenaline receptor family that is specifically expressed in intestinal stem cells ( Figure 1 A) The present inventors re-analyzed the single-cell transcriptome dataset of mouse small intestine and again noted that Adra2a is specific to Lgr5 + The expression of adrenergic receptors in the rest of the intestinal epithelial cells is low, and the expression of adrenergic receptors in the rest of the intestinal epithelial cells is low. Figure 1 B). By immunostaining ADRA2A in the intestinal epithelial tissue of Lgr5-GFP reporter mice, the inventors found that ADRA2A protein expression highly overlapped with Lgr5-GFP, consistent with the observation results of the transcriptome dataset, indicating that ADRA2A is specifically expressed in intestinal stem cells ( Figure 1 C). ADRA2A antibody staining results also showed that ADRA2A expression in stem cells has a memory distribution, and the receptors are concentrated on the side of the cells that is biased towards the intestinal cavity (top). The intestinal cavity is mainly distributed with abundant extracellular components, including food, microorganisms, mucus, etc. In view of the fact that intestinal microbial metabolites have become a rich source of potential GPCR ligands and can play a variety of physiological and pathological roles locally in the intestine, the inventors further explored whether bacterial metabolites would activate ADRA2A receptors expressed on intestinal stem cells (ISCs).
[0133] In order to further search for potential ADRA2A ligands from microbial-derived metabolites, the inventors screened ADRA2A based on the PRESTO-Tango GPCR method. ADRA2A was genetically edited so that its C-terminus was linked to the transcriptional regulatory factor-tetracycline transcription activator (tTA) through the tobacco etch virus nuclear inclusion A endopeptidase cleavage site sequence, and the β-Arrestin protease was genetically edited so that its C-terminus was coupled to the tobacco etch virus nuclear inclusion-endopeptidase (TEV) original. In cells expressing the tetracycline transcription activator (tTA)-luciferase reporter plasmid, the ADRA2A receptor binds to the ligand, activating the receptor while promoting the recruitment of the β-Arrestin protease, triggering the release of the tethered transcription factor tetracycline transcription activator (tTA), and inducing the expression of the luciferase reporter gene ( Figure 1 D). The inventors established a custom metabolite library containing 87 microbial metabolites enriched in the colon lumen, and screened all metabolites in the metabolite library using the PRESTO-Tango ADRA2A screening system. The inventors found that only tyramine can activate ADRA2A-Tango activity at a high level ( Figure 1 E). Tyramine is a trace monoamine with a structural formula highly consistent with norepinephrine (known ADRA2A ligand). It has sympathomimetic properties and is also used as a neurotransmitter in lower organisms to guide the sensory behavioral decisions of the Caenorhabditis elegans host. ( Figure 1 F).
[0134] Subsequently, the inventors used different concentrations of tyramine and norepinephrine (NorEpi) to perform ADRA2A-tango system detection. The maximum effect (Emax) of tyramine activating ADRA2A was 40% of the norepinephrine positive control; the average effective concentration (EC 50 ) was 180 nM, and the average effective concentration (EC 50 ) is 302μM( Figure 1 G). The inventors also used bioluminescence resonance energy transfer 2 (BRET2) detection to monitor the degree of dissociation of heterotrimeric G proteins induced by ADRA2A activation. In the inactivated state of GPCR, due to the aggregation of heterotrimeric G proteins, the fluorescent groups carried by the groups are in close contact, and the luminescent group RLuc8-Gα can effectively excite the fluorescent receptor GFP2-Gβγ, and the system detects the GFP signal; after GPCR activation, the dissociation of the heterotrimeric G protein complex causes the luminescent group RLuc8-Gα to be unable to effectively excite the fluorescent receptor GFP2-Gβγ, and the signal of GFP2 is reduced ( Figure 1 H). In the ADRA2A bioluminescence resonance energy transfer 2 (BRET2) detection system, tyramide activated ADRA2A to about 30% of the Emax of norepinephrine activation, the EC50 value of norepinephrine was 13 nM, and the EC50 value of tyramide was 42 μM ( Figure 1 I). These data suggest that tyramine is a ligand for ADRA2A and can effectively activate the Gi-cAMP signaling pathway.
[0135] Next, the inventors investigated whether the tyramine-ADRA2A signaling axis exists in patients with enteritis and what the possible effects are. The inventors explored the physiological and pathological concentrations of tyramine in the feces of healthy and IBD individuals. IBD includes two main types of diseases, Crohn's disease (CD) and ulcerative colitis (UC). Here, the inventors mainly focused on patients with Crohn's disease (CD). Through the separation and LC-MS quantification of tyramine in the feces of patients with Crohn's disease (CD), the inventors found that the level of tyramine in the feces of patients with Crohn's disease (CD) was significantly increased compared with the healthy control group ( Figure 1 J). In addition, the present inventors reanalyzed some public datasets and observed that ADRA2A expression was significantly increased in biopsy samples from Crohn's disease (CD) patients and in colon organoids expanded from intestinal stem cells (ISCs) from Crohn's disease (CD) patients ( Figure 1 K). These results suggest that the tyramine-ADRA2A signaling axis is enriched in a subset of Crohn's disease (CD) patients and influences the progression of intestinal inflammation.
[0136] Results and discussion: The experimental results of Example 1 show that intestinal stem cells have a tyramine-ADRA2A signaling axis, which mediates the interaction between intestinal bacteria and the host, and are enriched in intestinal inflammation, especially Crohn's disease, and have potential relevance to intestinal inflammation.
[0137] Example 2 Activation of the tyramine-ADRA2A signaling axis in intestinal stem cells inhibits cell proliferation
[0138] 1. Experimental process:
[0139] like Figure 2 As shown in A, the activation pattern diagram of the tyramine-ADRA2A signaling axis. The inventors used the intestinal organoid platform to explore the effect of tyramine-activated ADRA2A on intestinal stem cells, and introduced ADRA2A knockout mice to verify the ADRA2A dependence of the pathway at the genetic level.
[0140] 2. Experimental Model
[0141] Organoids represent one of the biggest revolutions in the biomedical field in the past decade. Organoids are 3D cell culture systems that are highly similar to the source tissues or organs in the body. These 3D systems are usually replicated and differentiated from pluripotent stem cells in specific tissue sites. This three-dimensional miniature organ structure cultured in vitro is very similar to the structure of tissues and organs. Under the action of 3D matrix gel and a variety of cytokines, a three-dimensional organ sample structure called intestinal organ sample was established by utilizing the regenerative ability of stem cells, which can simulate the characteristics of real intestinal organs, including morphology, function, and personalized response to specific stimuli. In addition, intestinal organoids are also an excellent model for studying the self-renewal and proliferation and differentiation functions of intestinal stem cells.
[0142] In order to study the effect of tyramine on the function of intestinal stem cells, the inventors established an intestinal organoid culture method, the specific method is as follows:
[0143] 1) Prepare 8-12 week old mice, euthanize them by dislocating the neck, take 6 cm small intestine and immerse it in a petri dish filled with cold PBS, flush the intestine with a 1 ml pipette, remove fat, and put it in clean PBS. (The pipette should be rinsed with 0.1% BSA in advance) Cut the intestine longitudinally, cut the intestine into 2-4 mm segments, drop it into a 50 ml centrifuge tube filled with 10 ml cold PBS, add 10 ml PBS, blow and aspirate 3 times, let it stand for 30 seconds to 1 minute, remove the supernatant as much as possible with a pipette, add 15 ml PBS, blow and aspirate 3 times, and discard the supernatant;
[0144] 2) Remove the supernatant as much as possible, add 20 ml of chelation buffer, and incubate at 4°C with gentle shaking for 30 min;
[0145] 3) Take a 15 ml centrifuge tube (6 small intestines), add a small amount of 0.1% BSA, shake gently on a shaker for 10 minutes, and discard the 0.1% BSA;
[0146] 4) Take out the centrifuge tube, let it stand and discard the supernatant, add 10 ml chelation buffer, pipette and pump 3 times, let it stand for 30 seconds, take the supernatant with a 1 ml gun (the gun tip is pre-prepared with 0.1% BSA) through a nylon mesh into the above 15 ml centrifuge tube, label 1, repeat this process 5 times for the small intestine, and obtain the suspension containing crypts numbered 1-5;
[0147] 5) Centrifuge each tube at 250g for 5 minutes at 4°C. You can see that crypt has settled at the bottom. Discard the supernatant, add 10ml 0.1% BSA to wash, pipette and aspirate 3 times, centrifuge at 250g for 5 minutes, and then add 0.1% BSA (10ml for the first 3 tubes and 5ml for the last 2 tubes).
[0148] 6) Take 250 μl of the suspension from each tube, add it to a 24-well plate, examine it under a microscope, select the suspension with crypts, but with fewer mixed cell clusters and single cells, and roughly count them under the microscope;
[0149] 7) Separate a suspension containing approximately 20-50 crypts, centrifuge at 250g for 5 minutes, estimate the location of the crypts, carefully remove the supernatant, replace the pipette tip that has been placed at -20℃ in advance, and add 24μl of 4℃ pre-cooled organoid culture medium (IntestiCult TM Organoid growth medium (StemCell Technologies, Cat.06005), then add 24μl matrigel (Corning, #356231 growth factor reduced), mix carefully, be careful of bubbles, take 47 μl of the mixed solution and seed it in the center of the well of a 24-well plate without bubbles to form a hemispherical shape, incubate at 37°C for 15 min, then take it out, add 500μl organoid culture medium, and fill 500μl PBS in the surrounding empty wells, observe the crypt state under a microscope, and culture it in a 5% CO2, 37°C constant temperature cell culture incubator, and change the organoid culture medium every 2 days;
[0150] 8) Tyramine (Selleckchem, S3625) was added to the organoid culture medium at the concentration indicated in the legend. The yohimbine treatment group required 2 h of pretreatment, followed by the addition of appropriate concentrations of tyramine or bacterial culture supernatant, and fresh culture medium was replaced after 6 h. After 4 days of culture, the organoids were imaged using a Leica THUNDER Imager 3D tissue microscope to calculate and evaluate the efficiency of organoid formation.
[0151] 9) After 4 days of culture, intestinal organoids were cultured in TrypLE TM Express (ThermoFisher Scientific, #12604013) was used to separate single cells, separated at 37°C for 10 minutes, and further analyzed by flow cytometry. The obtained single cells can be replanted in Matrigel, cultured as second organoids, or treated with tyramide (100 μM) for 16 hours to extract sample mRNA.
[0152] 3. Flow Cytometry Analysis to Detect Lgr5 + Intestinal stem cell ratio
[0153] After obtaining a single cell suspension according to the processing methods of different tissues and organs, subsequent flow cytometry fluorescence antibody labeling and flow cytometry detection can be performed. Generally, only the cell membrane surface antigen labeling detection experiment is required, 1×10 6The cells can meet the experimental requirements. Before antibody labeling, transfer the cells to a U-bottom 96-well plate according to the appropriate cell number, and then perform the following operations:
[0154] 1) Prepare a mixture of various fluorescent antibodies in advance, including anti-mouse CD16 / 32 FcR blocking solution before antibody labeling;
[0155] 2) Centrifuge at 500 g for 5 minutes at 4°C to collect the cell pellet, add 50 μL of FcR blocking solution to the cell pellet, gently blow the cells with a 300 μL pipette, and then incubate at 4°C for 15-20 minutes;
[0156] 3) Add 50 μL of the prepared antibody mixture, gently blow the cells with a 300 μL dispenser, and then incubate at 4°C in the dark for 20 to 30 minutes;
[0157] 4) Fill the 96-well plate with 1× PBS containing 1% FBS and centrifuge at 500 g for 5 minutes at 4°C to collect the cell pellet;
[0158] 5) For cells that are only labeled with cell membrane surface antigens, resuspend the cells in 200 μL of 1× PBS containing 1% FBS, filter through a 200-mesh nylon mesh into a new centrifuge tube, and then perform flow cytometry detection;
[0159] 6) All data were collected on a BECKMAN COULTER CytoFLEX S flow cytometer and analyzed using Flowjo software (TreeStar). The following antibodies were used: APC-CY7 anti-mCD45.2 (BioLegend, Clone104), APC anti-CD326 (EpCAM) (BioLegend, Clone G8.8), PE-CY7 anti-mCD24 (BioLegend, Clone M1 / 69), purified anti-CD16 / 32 (BioLegend, Clone 93) and DAPI (Bosterbio, AR1177);
[0160] 4. RNA Extraction, Reverse Transcription and RT-PCR
[0161] RNA extraction:
[0162] 1) Add 1 mL of TRNzol Universal to the obtained cell sample, then add 200 μL of chloroform (1 / 5 of the volume of TRNzol Universal), cover the centrifuge tube tightly, and vortex vigorously to mix thoroughly until the solution is emulsified and milky white. (Extracting RNA from tissue samples is similar, but the tissue samples need to be broken)
[0163] 2) Let stand at room temperature for 5 minutes. Then centrifuge at 12000g for 15 minutes at 4°C. Carefully remove the centrifuge tube from the centrifuge. The solution is now divided into three layers.
[0164] 3) Use a 200 μL pipette to carefully aspirate the top layer of liquid and transfer it to a new RNase free centrifuge tube. Be careful not to aspirate the middle white protein layer to prevent RNA contamination.
[0165] 4) Add 0.5-1 times the volume of isopropanol to the supernatant relative to the aspirated liquid, mix thoroughly by inverting, and place on ice for 10 minutes. If the amount of RNA is small, this step can be placed at -80℃ for precipitation overnight.
[0166] 5) Centrifuge at 12000g for 10 minutes at 4℃. Generally, RNA precipitate will appear at the bottom of the centrifuge tube after centrifugation.
[0167] 6) Wash RNA precipitate: Carefully discard the supernatant and do not touch the RNA precipitate. Add 500 μL of 75% ethanol solution prepared with DEPC water, gently invert the centrifuge tube upside down to wash the RNA precipitate and the wall of the centrifuge tube, centrifuge at 7500g at 4℃ for 5 minutes, then carefully discard the supernatant and do not touch the precipitate. Repeat the washing once.
[0168] 7) Dissolve RNA precipitate: Carefully open the centrifuge tube cap, dry the RNA precipitate at room temperature for 10-15 minutes (to allow the ethanol to evaporate), then add an appropriate amount of DEPC water and place at 4°C to dissolve the RNA precipitate. Finally, measure the RNA concentration before proceeding to the next step of the experiment.
[0169] Reverse transcription:
[0170] Prepare the reaction working solution on ice according to the following reaction system. To ensure the accuracy and sufficiency of the working solution, prepare the working solution according to the number of reactions + 1, then dispense it into each RNase free PCR tube, and finally add water and RNA sample in sequence.
[0171] a) Removal of genomic DNA
[0172] Prepare the reaction solution in a 200 μL RNase-free PCR tube according to the following reaction system, mix it by gently pipetting, and incubate it at 42°C in a PCR instrument for 2 minutes.
[0173]
[0174] b) RNA reverse transcription reaction
[0175] Directly add 5×HiScript III qRT SuperMix to the reaction system in the previous step. Use a pipette to gently pipette and mix well. Perform the reaction in a PCR instrument according to the following procedure: incubate at 37°C for 15 minutes, incubate at 85°C for 5 seconds, and incubate at 4°C for 5 minutes.
[0176]
[0177] 1) Real-time fluorescence quantitative PCR:
[0178] a) Prepare the working solution according to the following reaction system.
[0179]
[0180] b) Carry out RT-PCR reaction under the following conditions.
[0181]
[0182]
[0183] 2) The primer pairs used for the target gene are as follows:
[0184] mHprt-F:5'-TGTAATGATCAGTCAACGGGGG-3' (SEQ ID NO: 1);
[0185] mHprt-R:5'-AGAGGGTCCTTTTCACCAGCAA-3' (SEQ ID NO:2);
[0186] mRpl13a-F:5'-CGAGGTTGGCTGGAAGTACC-3' (SEQ ID NO:3);
[0187] mRpl13a-R:5'-CTTCTCGGCCTGTTTCCGTAG-3' (SEQ ID NO:4);
[0188] mCdc25a-F:5'-CCTACTGATGGCAAGCGTGTCA-3' (SEQ ID NO:5);
[0189] mCdc25a-R:5'-CTCATTGCCGAGCCTATCTCTC-3' (SEQ ID NO: 6);
[0190] 5. RNA Sequencing Sample Preparation and Sequencing Analysis
[0191] 1) Two pairs of 8-week-old littermate control male ADRA2AWT and ADRA2AKO mice were selected for in vitro organoid culture. The specific experimental steps refer to the "Intestinal Organoid Culture Experiment". After four days of culture, they were digested into single cells and treated with 100uM tyramide and control respectively. After 18 hours of treatment, TRIzol reagent (Invitrogen) was used to directly lyse the total RNA of in vitro amplified intestinal stem cells (ISC).
[0192] 2) The total RNA of ISC cells was extracted using the phenol-chloroform method.
[0193] 3) The total RNA was sent to Berry Genomics (Beijing) for processing and construction of mRNA library: Illumina sequencing was performed on the Novasek 6000 system.
[0194] 4) The raw RNA sequencing reads were aligned to the mouse genome (mm10, GRCm38) using STAR (v2.5.3a).
[0195] 5) Gene expression level and difference analysis were performed using edgeR (v3.29.2). Gene expression differences were considered significant when FoldChange ≥ 1.5 times and FDR < 0.05.
[0196] 6) Gene enrichment analysis was performed using online bioinformatics tools (metascape) and GSEA (v4.0.3), and volcano plots and path diagrams were drawn using the R package “ggplot2”.
[0197] 6. Experimental Results
[0198] like Figure 2 As shown in Figure B, by adding different concentrations of tyramine (0, 10, 50, 100 μM) during the organoid culture process, the organoid formation was observed. The experimental results showed that tyramine inhibited the formation of intestinal organoids in a dose-dependent manner, which directly reflects the activity of intestinal stem cells ( Figure 2 B, Figure 2 C). Meanwhile, the organogenesis capacity of ADRA2A-deficient cells was not affected by tyramine treatment, which reflects the role of tyramine-ADRA2A signaling axis in inhibiting the organogenesis capacity of intestinal stem cells.
[0199] like Figure 2 As shown in DF, by culturing intestinal organoids of Lgr5-GFP reporter mice, the inventors found that high concentrations of tyramine treatment inhibited the expression of Lgr5 + This indicates that at effective concentrations, tyramine inhibits the proportion of intestinal stem cells in single cells of intestinal organoids.
[0200] After analyzing the transcriptome changes in the tyramine-treated group, the inventors found that high concentrations of tyramine treatment inhibited the expression of Lgr5 + This indicates that at effective concentrations, tyramine down-regulated the cell cycle-related genes of intestinal stem cells, thereby inhibiting the proliferation of intestinal stem cells ( Figure 2 G, Figure 2 H). Regarding the changes in the CDC25a gene, the inventors performed a qPCR test on the transcriptome of intestinal stem cells and verified that the tyramine treatment group down-regulated the expression of the CDC25a gene, while ADRA2A knockout could restore the down-regulation of CDC25a.
[0201] Results and Discussion:
[0202] In Example 2, the inventors demonstrated that in an in vitro experiment of intestinal stem cells, tyramine activated ADRA2A and downregulated the expression of cell cycle-related genes, thereby inhibiting the proliferation of intestinal stem cells.
[0203] Example 3. Bioinformatics analysis confirmed that tyramine-producing enterococci are enriched in patients with enteritis
[0204] 1. Experimental process:
[0205] Use the Human Microbiome Project to analyze the distribution of tyrDC in the human microbiome. Analyze the differences in the microbiome of enteritis patient cohorts in different regions, and explore the distribution of enterococci in different regions and different disease states. At the same time, establish your own enteritis cohort to verify the distribution of enterococci in the Chinese population, which will facilitate subsequent functional verification and targeted treatment.
[0206] 2. Experimental results:
[0207] The inventors performed a BLASTP (Protein Basic Local Alignment Search Tool) search for TyrDC homologs in human intestinal bacteria against the Human Microbiome Project (HMP) reference genome and found that most of the matching sequence strains were located in the neighboring genus Enterococcus (84-100% homology) ( Figure 3 A). The results of this analysis indicate that Enterococcus spp. are the major producers of tyramine in the human gut microbiome, consistent with recently published metabolomics of the gut microbiome (data not shown).
[0208] Next, in order to further clarify the distribution of enterococci in the intestines of IBD patients, the inventors analyzed multiple genomic data and found that enterococci were generally enriched in the intestines of Crohn's disease (CD) patients through omics analysis of multiple cohorts, and were regionally conserved. By analyzing the intestinal microbiota composition of IBD cohorts from three different geographical locations in France, Israel and the United States (n=537), the control group consisted of unrelated healthy individuals. Consistent with the article report, the results of shotgun metagenomic analysis of fecal samples from the four cohorts showed that the microbial richness of Crohn's disease (CD) patients was low (p value <0.0001). By analyzing the differential strains, this article found that enterococci were generally enriched in the intestines of Crohn's disease (CD) patients in the three cohorts in France, Israel and the United States ( Figure 3 B). In addition, this paper analyzed the distribution of different strains in Crohn's disease (CD) patients in different disease states in the above cohort, including stable stage (mild inflammation) and progressive stage (severe inflammation). The analysis results showed that enterococci were enriched in patients with progressive Crohn's disease (CD) ( Figure 3 C). This result suggests that the distribution of enterococci may aggravate the progression of intestinal inflammation. In addition, this article independently collected and analyzed the composition of intestinal microbiota in patients with IBD cohort (USTC) (n=51), and found that enterococci were enriched in patients with Crohn's disease (CD) ( Figure 3 C), which is consistent with the analysis on appeal.
[0209] The inventors established an IBD cohort center (University of Science and Technology of China, USTC), and the control group consisted of unrelated healthy individuals. Under the ethical review of clinical sample collection and analysis, stool samples from patients with Crohn's disease (CD, n = 51) were collected and liquid chromatography-mass spectrometry was performed to detect intestinal tyramine levels ( Figure 1 J) and gut microbiota composition ( Figure 3 DF). The inventors conducted an experiment on 16S rDNA sequencing of intestinal microorganisms in a Crohn's disease cohort. The inventors first independently collected and analyzed feces from healthy donors (n=36) and Crohn's disease (CD) patients (n=51), stored at -80°C, and established the USTC CD cohort. Then, fecal DNA was extracted, a library was built, and 16S rDNA was sequenced and analyzed. The inventors used both unweighted and weighted UniFrac distance analysis (PCOA), and the P value was tested using permutation multivariate ANOVA (PERMANOVA). 100,000 permutations ( Figure 3D), and the results showed that the fecal bacterial composition of healthy donors and CD patients was significantly different. Further differential component analysis using LefSe found that the inflammatory commensal bacteria Escherichia-Shigella and Proteus, which are closely related to IBD, were enriched in the fecal samples of CD patients; at the same time, the probiotics Prevotella and Faecalibacterium were enriched in the fecal samples of healthy people ( Figure 3 CE). At the same time, the inventors found that Enterococcus was also enriched in CD patients ( Figure 3 CE), which is consistent with the results of multiple CD cohort analyses in different regions.
[0210] Results and Discussion:
[0211] In summary, enterococci are enriched in the intestines of patients with Crohn's disease (CD) from different geographical cohorts and are positively correlated with disease progression, which may aggravate the progression of intestinal inflammation. This result is consistent with the role of enterococcal-derived tyramine in promoting colitis in experimental colitis.
[0212] Example 4. Effect of the Enterococcus-Tyramine-ADRA2A Signaling Axis in a Mouse Enteritis Model
[0213] 1.DSS-induced colitis model in mice
[0214] The colitis model induced by dextran sulfate sodium salt (DSS) is one of the most commonly used rodent models for studying IBD. The symptoms of this colitis model are similar to the clinical symptoms of UC patients, mainly manifested as diarrhea, weight loss, fecal occult blood, etc. In order to simulate the pathogenesis of human inflammatory bowel disease, the inventors used a DSS (MP Biomedicals) chemically induced colitis model, and the specific method is as follows:
[0215] 1) Prepare 4 to 6 pairs of 8-week-old control mice of the same sex and litter. On day 0, mark the mice and weigh them, then prepare a 2.5% DSS solution and feed them. Note: Each mouse needs about 5 to 8 mL of DSS solution per day, and make sure that the DSS solution is not completely consumed.
[0216] 2) Weigh the mice regularly every day and observe the status of their feces: the feces will gradually become thinner, and in severe cases, blood in the stool will appear. Colonoscopy can also be used to monitor and evaluate colitis.
[0217] 3) The DSS solution needs to be replaced every 3-4 days. For acute DSS models, it is usually sufficient to prepare it twice.
[0218] 4) During the experiment, the DSS aqueous solution was replaced with regular drinking water according to the weight changes, blood in stool, etc. of the mice. Note that DSS was generally discontinued when the body weight dropped below 95%. The model was successfully established only if the weight of the mice continued to drop after discontinuation. The mice needed to be sacrificed when the body weight dropped below 70%.
[0219] 5) After DSS modeling, mice were killed, colon length was measured and colon tissue samples were collected for histological pathological analysis. According to IACUC guidelines, mice need to be euthanized once they lose more than 30% of their initial body weight after colitis induction. For histological examination, the colon tissue of mice was fixed with 4% formalin buffer immediately after euthanasia and stored at 4°C overnight. After fixation, the samples were transferred to 70% ethanol and then wrapped with wax. 5 mm thick sections were cut in the sagittal plane and stained with hematoxylin and eosin.
[0220] 6) The severity of colitis was assessed based on the pathological grading of H&E-stained sections (Wirtz et al., 2017). The pathological sections were stained with H&E, photographed and scanned for double-blind pathological scoring. Briefly, these sections were scored by two researchers in a double-blind manner, based on the number of inflammatory cell infiltrations (0-none; 1-isolated focal epithelial damage; 2-mucosal erosions and ulcers; 3-extensive damage deep into the intestinal wall) and tissue damage (0-uncommon; 1-increased, some neutrophils; 2-inflammatory cell clusters present under the mucosa; 3-transmural cell infiltration). The combined score of the sum of the two sub-scores ranged from 0 (no change) to 6 (extensive cell infiltration and extensive tissue damage). The histopathology scoring criteria include:
[0221]
[0222]
[0223] 2. SPF mouse colonization, DSS model induction and yohimbine treatment
[0224] 1) Prepare 8-12 week old mice of the same sex from the same litter. The mice were fed with ABX concentrate (dissolved in 1×PBS) containing ampicillin sodium (10 g / L), neomycin sulfate (10 g / L), metronidazole (10 g / L) and vancomycin hydrochloride (5 g / L) by gavage once a day for three days. The feces of the mice were collected once before and after the start of antibiotic feeding to detect the effect of intestinal flora clearance.
[0225] 2) After the experimental mice were cleaned of their intestines, they were colonized with enterococci (10^9 CFU of enterococci per mouse, administered orally every 2 days for 2 weeks).
[0226] 3) After the single bacterial colonization of the experimental mouse intestine was completed, the fecal microbiota transplantation (FMT) method was used to reconstruct the intestinal flora of the experimental mice to facilitate the subsequent construction of the DSS-induced intestinal verification model. FMT was performed according to the protocol of the reference. In short, fecal microspheres from normal and healthy wild-type mice were harvested under sterile conditions, suspended in sterile 10% glycerol at a concentration of 50 mg / mL, and orally administered at a dose of 10 mg per mouse. One day later, 2.5% DSS was added to the drinking water to induce a mouse colitis model. In addition, yohimbine was used to treat the colitis model, and additional yohimbine injections were added. The specific plan is to inject yohimbine (2 mg / kg) intraperitoneally every other day starting one week after enterococcal colonization, for a total of 8 injections.
[0227] 3. Experimental results:
[0228] In IBD, inhibition of ISC proliferation disrupts epithelial barrier reconstruction and exacerbates colitis. Therefore, the inventors further explored whether tyramine inhibition of intestinal stem cells (ISCs) would aggravate experimental intestinal inflammation, such as dextran sodium sulfate (DSS)-induced colitis models. The inventors gave ADRA2A △IEC Mice and their littermates ADRA2A WT The control group mice were given tyramine by water feeding (including the water control group) for 4 weeks, and then the DSS colitis model was induced ( Figure 4 A). By measuring weight loss ( Figure 4 B) Colon length ( Figure 4 C, Figure 4 D) Histopathological changes of intestinal inflammation and tissue damage (including colon thickness, architectural distortion, and inflammatory cell infiltration) Figure 4 E, Figure 4 F) to assess the severity of colitis, the inventors observed that in ADRA2A WT In mice, tyramine exposure resulted in a significant increase in colitis severity compared with water, whereas ADRA2A △IEC In mice, the severity of tyramine-mediated colitis was significantly attenuated. These results suggest that tyramine aggravates DSS-induced colitis through ADRA2A.
[0229] To further demonstrate the pathogenic role of enterococcal tyramine in promoting colitis, the present inventors inoculated wild-type mice pretreated with antibiotics with WT and tyrDC-deficient Enterococcus faecalis strains by oral administration and then induced a DSS colitis model ( Figure 4A). After single bacterial colonization, the inventors used liquid chromatography-mass spectrometry to detect the content of tyramine in mouse feces and found that both strains successfully colonized mice, and the tyramine content in mouse feces was significantly different (data not provided). After 2.5% DSS induction, mice colonized with tyrDC-deficient Enterococcus faecalis showed a mitigated colitis phenotype, including weight loss, colon length, and histopathological changes, compared with mice colonized with WT strains. Figure 4 These results suggest that enterococci produce tyramine via tyrDC, thereby aggravating DSS-induced colitis.
[0230] At the same time, the inventors also wanted to know whether the aggravation of enterococci on enteritis depends on the ADRA2A receptor on intestinal stem cells (ISCs). The inventors inoculated WT and tyrDC-deficient Enterococcus faecalis strains into ADRA2A cells pretreated with antibiotics. △IEC In mice, the DSS colitis model was then induced ( Figure 4 M). After 2.5% DSS induction, mice colonized with tyrDC-deficient E. faecalis exhibited the same colitis phenotypes as those colonized with the WT strain, including weight loss, colon length, mortality, and histopathological changes. Figure 4 NR). These results suggest that enterococci produce tyramine through tyrDC and depend on ADRA2A expressed on intestinal stem cells (ISCs), aggravating DSS-induced colitis.
[0231] Results and Discussion:
[0232] This in vivo experiment showed that the Enterococcus-tyramine-ADRA2A signaling axis aggravated the development of intestinal inflammation in mice, and blocking this signaling axis could restore intestinal epithelial repair and alleviate the progression of intestinal inflammation.
[0233] Example 5. ADRA2A antagonists can block the aggravating effect of patient-derived enterococcal strains on enteritis
[0234] 1. Intestinal organoid culture
[0235] The experimental subjects were mouse intestinal organoids cultured in vitro to verify the blocking effect of ADRA2A antagonists on tyramine-activated ADRA2A on intestinal stem cells. The specific methods are as follows:
[0236] 1) Prepare 8-12 week old mice, euthanize them by dislocating the neck, take 6 cm small intestine and immerse it in a petri dish filled with cold PBS, flush the intestine with a 1 ml pipette, remove fat, and put it in clean PBS. (The pipette should be rinsed with 0.1% BSA in advance) Cut the intestine longitudinally, cut the intestine into 2-4 mm segments, drop it into a 50 ml centrifuge tube filled with 10 ml cold PBS, add 10 ml PBS, blow and aspirate 3 times, let it stand for 30 seconds to 1 minute, remove the supernatant as much as possible with a pipette, add 15 ml PBS, blow and aspirate 3 times, and discard the supernatant.
[0237] 2) Remove the supernatant as much as possible, add 20 ml of chelation buffer, and incubate at 4°C with gentle shaking for 30 minutes.
[0238] 3) Take a 15 ml centrifuge tube (6 small intestines), add a small amount of 0.1% BSA, shake gently on a shaker for 10 minutes, and discard the 0.1% BSA.
[0239] 4) Take out the centrifuge tube, let it stand and discard the supernatant, add 10 ml of chelation buffer, pipette and pump three times, let it stand for 30 seconds, then use a 1 ml gun (the gun tip is pre-prepared with 0.1% BSA) to take the supernatant through the nylon mesh into the above-mentioned 15 ml centrifuge tube, label 1. Repeat this process 5 times for the small intestine to obtain the suspension containing crypt numbered 1-5.
[0240] 5) Centrifuge each tube at 250g for 5 minutes at 4°C. You can see that the crypt has settled at the bottom. Discard the supernatant, add 10ml 0.1% BSA for washing, pipette up and down 3 times, centrifuge at 250g for 5 minutes, and then add 0.1% BSA (10ml for the first 3 tubes and 5ml for the last 2 tubes).
[0241] 6) Take 250 μl of the suspension from each tube, add it to a 24-well plate, examine it under a microscope, select the suspension with crypt, but with fewer mixed cell clusters and single cells, and roughly count them under the microscope.
[0242] 7) Separate a suspension containing approximately 20-50 crypts, centrifuge at 250g for 5 minutes, estimate the location of the crypts, carefully remove the supernatant, replace the pipette tip that has been placed at -20℃ in advance, and add 24μl of 4℃ pre-cooled organoid culture medium (IntestiCult TM06005)), then add 24μl matrigel (Corning, #356231 growth factor reduced), mix carefully, be careful of bubbles, take 47μl of the mixture and plant it in the center of the well of a 24-well plate without bubbles to form a hemispherical shape, incubate at 37℃ for 15min, then take it out, add 500μl organoid culture medium, and fill 500μl PBS into the surrounding empty wells, observe the crypt state under the microscope, put it in a 5% CO2, 37℃ constant temperature cell culture incubator for culture, and change the organoid culture medium every 2 days.
[0243] 8) Tyramine (Selleckchem, S3625), yohimbine (Selleckchem, S2373), imidazoxan (MCE, HY-14561A) and 2-methoxyimidazolidin (MCE, HY-103197) were added to the organoid culture at concentrations of 100 μM, 10 μM, 10 μM, and 10 μM, respectively. ADRA2A antagonists, including yohimbine, imidazoxan and 2-methoxyimidazolidin, require 2 h of pretreatment, followed by the addition of appropriate concentrations of tyramine or bacterial culture supernatant, and fresh culture medium was replaced every two days. After 4 days of culture, the organoids were imaged using a Leica THUNDER Imager 3D tissue microscope to calculate and evaluate the efficiency of organoid formation.
[0244] 2. Isolation and culture of clinical Enterococcus faecalis strains in IBD
[0245] 1) Prepare fresh stool samples from IBD patients and store them in 1×PBS (25% glycerol, autoclaved).
[0246] 2) Use a tissue disruptor to disrupt and resolve the sample, and dilute the fecal sample and smear it on a GAM bacterial anaerobic medium solid agar plate, which consists of 1.0% (w / v) animal tissue digestion enzyme digestion solution, 0.3% soybean meal digestion solution, 1.0% protease peptone, 1.35% digested serum, 0.5% yeast extract, 0.22% beef extract, 0.12% liver extract, 0.3% glucose, 0.25% potassium dihydrogen phosphate, 0.3% sodium chloride, 0.5% soluble starch, 0.03% l-cysteine salt base, 0.25% potassium dihydrogen phosphate, 0.03% l-cysteine, and 0.03% sodium thioacetate, with a final pH of 7.3±0.1.
[0247] 3) After culturing in an anaerobic chamber under strict anaerobic conditions (80% N2, 10% H2, 10% CO2) for 2-4 days, a single colony was picked, cultured and identified. The primers used for identification were: universal primers (16S-27f: 5'agagtttgatcmtggctcag3', 16S-1492r: 5'-tacggytaccttgttacgtt-3'), and 16S rRNA gene sequencing was performed for classification identification.
[0248] 4) The isolated strain was identified as a single strain of Enterococcus through 16S PCR identification and whole genome sequencing, and was named and aliquoted and frozen in a -80°C refrigerator. The freezing medium was GAM liquid culture medium containing 25% glycerol for subsequent use.
[0249] 3.DSS-induced colitis model in mice
[0250] The colitis model induced by dextran sulfate sodium salt (DSS) is one of the most commonly used rodent models for studying IBD. The symptoms of this colitis model are similar to the clinical symptoms of UC patients, mainly manifested as diarrhea, weight loss, fecal occult blood, etc. In order to simulate the pathogenesis of human inflammatory bowel disease, the inventors used a DSS (MP Biomedicals) chemically induced colitis model, and the specific method is as follows:
[0251] 1) Prepare 4 to 6 pairs of 8-week-old control mice of the same sex and litter. On day 0, mark the mice and weigh them, then prepare a 2.5% DSS solution and feed them. Note: Each mouse needs about 5 to 8 mL of DSS solution per day, and make sure that the DSS solution is not completely consumed.
[0252] 2) Weigh the mice regularly every day and observe the status of their feces: the feces will gradually become thinner, and in severe cases, blood in the stool will appear. Colonoscopy can also be used to monitor and evaluate colitis.
[0253] 3) The DSS solution needs to be replaced every 3-4 days. For acute DSS models, it is usually sufficient to prepare it twice.
[0254] 4) During the experiment, the DSS aqueous solution was replaced with regular drinking water according to the weight changes, blood in stool, etc. of the mice. Note that DSS was generally discontinued when the body weight dropped below 95%. The model was successfully established only if the weight of the mice continued to drop after discontinuation. The mice needed to be sacrificed when the body weight dropped below 70%.
[0255] 5) After DSS modeling, mice were killed, colon length was measured and colon tissue samples were collected for histological pathological analysis. According to IACUC guidelines, mice need to be euthanized once they lose more than 30% of their initial body weight after colitis induction. For histological examination, the colon tissue of mice was fixed with 4% formalin buffer immediately after euthanasia and stored at 4°C overnight. After fixation, the samples were transferred to 70% ethanol and then wrapped with wax. 5mm thick sections were cut in the sagittal plane and stained with hematoxylin and eosin.
[0256] 6) The severity of colitis was assessed based on the pathological grading of H&E-stained sections (Wirtz et al., 2017). The pathological sections were stained with H&E, photographed and scanned for double-blind pathological scoring. Briefly, these sections were scored by two researchers in a double-blind manner, based on the number of inflammatory cell infiltrations (0-none; 1-isolated focal epithelial damage; 2-mucosal erosions and ulcers; 3-extensive damage deep into the intestinal wall) and tissue damage (0-uncommon; 1-increased, some neutrophils; 2-inflammation cell clusters present under the mucosa; 3-transmural cell infiltration). The combined score of the sum of the two sub-scores ranged from 0 (no change) to 6 (extensive cell infiltration and extensive tissue damage). The histopathological scoring criteria include:
[0257]
[0258] 4. Experimental results:
[0259] After treatment with ADRA2A receptor antagonists, the inhibitory effect of tyramine-activated ADRA2A on intestinal stem cells was significantly inhibited ( Figure 5 AC, *p < 0.05, ****p < 0.0001). The results showed that ADRA2A antagonists could interfere with enterococci through the tyramine-ADRA2A signaling axis and aggravate the progression of intestinal inflammation.
[0260] The inventors further obtained patient-derived strains through culture omics to verify disease relevance. The inventors obtained a patient-derived enterococcal strain named Enterococcus faecium CD30 (E. faecium CD30). The DSS enteritis model was induced by colonization of single enterococci ( Figure 5 D), the inventors have demonstrated that E. faeciumCD30 can inhibit the proliferation of intestinal stem cells, hinder intestinal epithelial repair, and aggravate the progression of intestinal inflammation through the tyramine-ADRA2A signaling axis on intestinal stem cells ( Figure 5 EI). The experimental results indicate that clinically relevant enterococci can aggravate the progression of enteritis in patients through the tyramine-ADRA2A signaling axis on intestinal stem cells.
[0261] The inventors further verified the potential of ADRA2A antagonists in the treatment and intervention of patients with enterococcal-enriched intestinal inflammation. The inventors implemented yohimbine intervention in the above DSS-induced mouse enteritis model ( Figure 5 D). The results showed that enterococci significantly restored the aggravating effect of clinical enterococci on enteritis ( Figure 5 EI). The experimental results showed that ADRA2A antagonists play an important and significant role in preventing and treating enterococcal-enriched intestinal inflammation.
[0262] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. Use of an antagonist of the tyramine-ADRA2A signaling axis in the preparation of a drug for preventing and / or treating inflammatory bowel disease and restoring stem cell growth / organoid growth.
2. The use according to claim 1, characterized in that The antagonist of the tyramine-ADRA2A signaling axis is a tyramine inhibitor.
3. The use according to claim 2, characterized in that The tyramine inhibitor is a substance that inhibits the production of tyramine by related microorganisms, for example: 3-fluoro-alpha-fluoromethyltyrosine (CAS: 73804-76-9).
4. The use according to claim 1, characterized in that The antagonist of the tyramine-ADRA2A signaling axis is an ADRA2A antagonist.
5. The use according to claim 4, characterized in that The ADRA2A antagonists include, but are not limited to, small molecule inhibitors of ADRA2A, monoclonal antibodies of ADRA2A, and siRNA of the gene encoding ADRA2A.
6. The use according to claim 5, characterized in that The small molecule antagonists of ADRA2A include, but are not limited to, yohimbine, idazoxan and 2-methoxyimidazolidine; yohimbine is preferred.
7. The use according to any one of claims 1 to 6, characterized in that The inflammatory bowel disease includes, but is not limited to, Crohn's disease and ulcerative colitis; preferably, Crohn's disease.
8. A pharmaceutical composition comprising an antagonist of tyramine-ADRA2A signaling axis and other therapeutic drugs for inflammatory bowel disease and a pharmaceutically acceptable excipient.
9. An antagonist of the tyramine-ADRA2A signaling axis or a pharmaceutical composition comprising the antagonist of the tyramine-ADRA2A signaling axis for use in preventing and / or treating inflammatory bowel disease.
10. Use of tyramine in inhibiting intestinal stem cells or preparing intestinal stem cell inhibitors.
Citation Information
Patent Citations
Anti-inflammatory compositions and combinations
CN101925354A
Methods of treating colitis
CN108348558A
Application of isoginkgetin in preparation of medicine for preventing and / or treating ulcerative colitis
CN116036072A
Application of yohimbine medicine in treatment of type 2 diabetes mellitus
CN116999439A
Methods of treating inflammatory conditions with adrenergic antagonists
US20110195974A1
